KLRC1 and Miyoshi myopathy: While this study focused on the regulatory effect of RNA Pol I inhibitors on HLA-E/NKG2A regulatory activity within the context of MM and NK cell responses, further investigations will be necessary to define the repertoire of binding peptides presented by HLA-E (and classical HLA-I), in cells treated with this class of drugs.